WASHINGTON (Reuters) – U.S. lawmakers on both sides and both houses of Congress have introduced eight antitrust bills aimed at addressing the problem of high and rising drug prices, including bills to prevent companies Branded pharmaceuticals pay generic companies to stay out of the market.
At an unusual hearing of the House Judiciary Antitrust Panel on Thursday, lawmakers from both sides and the Senate and House said they had introduced bills to stop practices that pharmaceutical companies use to defend competition. generic, which studies show to lower prices.
“Millions of Americans began their day with a dose of prescription drugs. Unfortunately, for many patients, these drugs are not affordable. Prescriptions are left on the pharmacy counter. Doses are omitted or rationed. until the next salary.
That’s unacceptable, ”Republican Sen. Chuck Grassley said in the House hearing.
Two of the bills, one in the House and one in the Senate, are aimed at stopping the jump in products or making a minor change to a drug to win a new patent.
Others would try to ban late-payment patent agreements, where branded pharmaceutical companies pay for generic products to delay market entry. Another allows the Federal Trade Commission to ban false requests from citizens, where pharmaceutical companies apply to the Food and Drug Administration for a generic company to seek approval for a drug rival to the Food and Drug Administration. aim to delay its approval.
And one last pair is aimed at facilitating the commercialization of biosimilars, essentially generic versions of biological drugs. These drugs are more complicated than chemical drugs because they include living organisms.
Each of the bills has a Republican lawmaker and a Democrat as a sponsor of the House and Senate versions. To become law, bills must go through the House and Senate and be signed by the president.